Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

407

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
HIV-1 InfectionAIDS
Interventions
DRUG

Maraviroc (Celsentri)

"Patients will take cART optimized regimen according to the recommended regimen as first line of treatment in most commonly used guidelines with Maraviroc at the following dose: 150 mg orally twice a day for patients receiving a Protease Inhibitor Ritonavir-boosted regimen (except Fosamprenavir), 300 mg orally twice a day for patients receiving a Fosamprenavir Ritonavir-boosted regimen or 600 mg orally twice a day for patients receiving Efavirenz-based regimen.~Duration: 72 weeks."

DRUG

Placebo

"Patients will take cART optimized regimen according to the recommended regimen as first line of treatment in most commonly used guidelines with Placebo at the following dose: 150 mg orally twice a day for patients receiving a Protease Inhibitor Ritonavir-boosted regimen (except Fosamprenavir), 300 mg orally twice a day for patients receiving a Fosamprenavir Ritonavir-boosted regimen or 600 mg orally twice a day for patients receiving Efavirenz-based regimen.~Duration: 72 weeks."

Trial Locations (1)

94010

Hôpital Henri Mondor, Créteil

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

ANRS, Emerging Infectious Diseases

OTHER_GOV

NCT01348308 - Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients | Biotech Hunter | Biotech Hunter